US 7052906B1
· Lawson et al.
· 2006
[cited by applicant]
US 7635472B2
· Kufer et al.
· 2009
[cited by applicant]
US 8007796B2
· Baeuerle et al.
· 2011
[cited by applicant]
US 9868774B2
· Orentas et al.
· 2018
[cited by applicant]
US 20130266551A1
· Campana et al.
· 2013
[cited by applicant]
US 20160296562A1
· Pule et al.
· 2016
[cited by applicant]
US 20190038672A1
· Pule et al.
· 2019
[cited by applicant]
US 20190330337A1
· Pule et al.
· 2019
[cited by applicant]
US 20200181232A1
· Puléet al.
· 2020
[cited by applicant]
US 20210187026A1
· Pule et al.
· 2021
[cited by applicant]
US 20240033289A1
· Pulé
· 2024
[cited by examiner]
GB 1507111A
· 1978
[cited by applicant]
GB 14231724
· 2014
[cited by applicant]
GB 15071111
· 2015
[cited by applicant]
WO 0063372A1
· 2000
[cited by applicant]
WO 2012079000A1
· 2012
[cited by applicant]
WO 2013059593A1
· 2013
[cited by applicant]
WO 2013123061A1
· 2013
[cited by applicant]
WO 2013185552A1
· 2013
[cited by applicant]
WO 2014011988A2
· 2014
[cited by applicant]
WO 2014055657A1
· 2014
[cited by applicant]
WO 2014055668A1
· 2014
[cited by applicant]
WO 2014065961A1
· 2014
[cited by applicant]
WO WO2014124143A1
· 2014
[cited by applicant]
WO 2014138704A1
· 2014
[cited by applicant]
WO 2014145252A2
· 2014
[cited by applicant]
WO 2014184143A1
· 2014
[cited by applicant]
WO 2015075468A1
· 2015
[cited by applicant]
WO 2015075470A1
· 2015
[cited by applicant]
WO 2015092024A2
· 2015
[cited by applicant]
WO 2015142314A1
· 2015
[cited by applicant]
WO 2016139487A1
· 2016
[cited by applicant]
WO 2016174405A1
· 2016
[cited by applicant]
WO 2016210293A1
· 2016
[cited by applicant]
WO 2017216561A1
· 2017
[cited by applicant]
WO 2017216562A1
· 2017
[cited by applicant]
Bonini and Mondino (Eur. J. Immunol. 2015 45: 2457-2469) (Year: 2015).
[cited by examiner]
Chen and Flies (Nature Review Immunology, Apr. 2013, 12: 227-242) (Year: 2013).
[cited by examiner]
Almagro et al., Humanization of antibodies, Front. Biosci., 13:1619-33 (2008).
[cited by applicant]
Amrolia et al., Chimeric Antigen Receptor T Cells for ALL, Lancet, 385:488-490 (2015).
[cited by applicant]
Bejcek et al., Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen, Cancer Res., 55(11):2346-51 (1995).
[cited by applicant]
Brentjens et al., “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15,” Nature Medicine 9(3):279-286 (2003).
[cited by applicant]
Bridgeman, et al., “The Optimal Antigen Response of Chimeric Antigen Receptors Harboring the CD3(zeta) Transmembrane Domain is Dependent upon Incorporation of the Receptor into the Endogenous TCR/CD3 Complex,” J. Immuno…
[cited by applicant]
Burns, et al., “A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas,” Cancer Res; 70(8), pp. 3027-3033 (Apr. 2010).
[cited by applicant]
Campana et al., Human B cell development. I. Phenotypic differences of B lymphocytes in the bone marrow and peripheral lymphoid tissue, J. Immunol., 134(3):1524-30 (1985).
[cited by applicant]
Campana et al., Immunophenotyping of leukemia, J. Immunol. Methods, 243(1-2):59-75 (2000).
[cited by applicant]
Chen, et al., “Fusion Protein Linkers: Property, Design and Functionality,” Adv Drug Deliv Rev, 65(10):1357-1369 (Oct. 2013).
[cited by applicant]
Chicaybam et al., “Moving Receptor Redirected Adoptive Cell Therapy Toward Fine Tuning of Antitumor Responses,” International Reviews of Immunology 33:402-416 (2014).
[cited by applicant]
Chmielewski, et al., “Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells,” Frontiers in Immunology, Tumor Immunity, 4(371):1-7 (2013).
[cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Biomolecular Research Institute, 145(1): 33-36 (1994).
[cited by applicant]
Cordoba, et al., “The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor,” Blood, 121(21):4295-4302 (2013).
[cited by applicant]
Courtney, et al., “TCR Signaling: Mechanisms of Initiation and Propagation,” Trends Biochem Sci., 43(2):108-123 (Feb. 2018).
[cited by applicant]
De Felipe, “Polycistronic Viral Vectors,” Current Gene Therapy; 2(3):355-378 (2002).
[cited by applicant]
Dijoseph et al., Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22, Cancer Immunol. Immunother., 54(1):11-24 (2005).
[cited by applicant]
Dolezal, et al., “ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in a single-chain Fv fragment assembled in VL to VH orientation drives the formation of dimers, trimers, tetramers and h…
[cited by applicant]
Donnelly et al., The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurrina ‘2A-like’ sequences, J. Gen. Viral. 82: 1027-41 (2001 ).
[cited by applicant]
Dorken et al., HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes, J. Immunol., 136(12):4470-9 (1986).
[cited by applicant]
Dotti et al., Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells, Immunol. Rev. 257:1-30 (2014).
[cited by applicant]
Engel et al., Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand, J. Exp. Med., 181(4):1581-6 (1995).
[cited by applicant]
Fedorov et al., “PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Taraet Immunotheraov Responses,” Science Translation Medicine 5(215), 13 pages (2013).
[cited by applicant]
Gerdes et al., Emerging understanding of multiscale tumor heterogeneity, Frontiers in oncology, 4:366 (2014).
[cited by applicant]
Ghetie et al., “The Antitumor Activity of an Anti-CD22 Immunotoxin in SCIO Mice With Disseminated Daudi Lymphoma Is Enhanced by Either an Anti-CD19 Antibody or an Anti-CD19 Immunotoxin,” Blood 80(9):2315-2320 (1992).
[cited by applicant]
Grada et al., TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy, Mol. Ther. Nucleic Acids, 2:e105 (2013).
[cited by applicant]
Grupp et al., Chimeric antigen receptor-modified T cells for acute lumphoid leukemia. N. Engl. J. Med. 368(16): 1509-18 (2013).
[cited by applicant]
Guedan et al., Enhancing CART cell persistence through ICOS and 4-1 BB costimulation., JCL Insight,. doi: 10.1172/jci.insight.96976 (2018).
[cited by applicant]
Guha, et al., “Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased (alpha)5(beta)1 integrin expression,” Journal of Leukocyte Biology, vol. 102, pp. 201-208 (Aug. 2017).
[cited by applicant]
Haso et al., Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood, 121(7):1165-1174 (2013).
[cited by applicant]
Hegde et al., Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma, Mol. Ther., 21(11):2087-101 (2013).
[cited by applicant]
Hege, et al., “Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer,” Journal for Immuno Therapy of Cancer, 5:22, pp. 1-14 (2017).
[cited by applicant]
Herbst et al., B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody, J. Pharmacol. Exp. Ther., 335(1):213-22 (2010).
[cited by applicant]
Hombach et al., Costimulation by Chimeric Antigen Receptors Revisited: the T Cell Antitumor Response Benefits from Combined CD28-OX40 Signalling, International Journal of Cancer, 129:2935-2944 (2011).
[cited by applicant]
Hudecek et al., “The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity,” Cancer Immunoloav Research 3(2):125-135 (2015).
[cited by applicant]
International Application No. PCT/GB2015/054137, International Preliminary Report on Patentability, mailed Jul. 6, 2017.
[cited by applicant]
International Application No. PCT/GB2015/054137, International Search Report and Written Opinion, mailed Jun. 6, 2016.
[cited by applicant]
James et al., Antigen sensitivity of CD22-specific chimeric TCR Is modulated by target epitope distance from the cell membrane, J. Immunol., 180:7028-7038 (2008).
[cited by applicant]
Jena et al., Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials, PLOS One, 8:e57838 (2013).
[cited by applicant]
Jena et al., Driving CAR-based T-cell therapy to success, Curr. Hematol. Malig. Rep., 9(1):50-6 (2014).
[cited by applicant]
Jena et al., Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, 116(7):1035-1044 (2010).
[cited by applicant]
Jensen et al., Design and implementation of adoptive therapy with chimeric antigen receptor-modified t cells, Immunol. Rev., 257:127-44 (2014).
[cited by applicant]
John et al., The B cell coreceptor CD22 associates with AP50, a clathrin-coated pit adapter protein, via tyrosine-dependent interaction, J. Immunol., 170(7):3534-43 (2003).
[cited by applicant]
Kaiser, Cancer. First pass at cancer genome reveals complex landscape, Science, 8;313(5792):1370 (2006).
[cited by applicant]
Kansas et al., Transmembrane signals generated through MHC class II, CD19, CD20, CD39, and CD40 antigens induce LFA-1-dependent and independent adhesion in human B cells through a tyrosine kinase-dependent pathway, J. I…
[cited by applicant]
Kipriyanov et al., “Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity,” Protein Engineering 10(4):445-453 (1997).
[cited by applicant]
Kipriyanov et al., Rapid detection of recombinant antibody fragments directed against cell-surface antigens by flow cytometry, J. Immunol. Meth. 196:51-62 (1996).
[cited by applicant]
Kloss et al., “Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells,” Nature Biotechnology 31 (1 ):71-75 (2013).
[cited by applicant]
Kochenderfer et al., Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor, J. Immunother., 32(7):689-702 (2009).
[cited by applicant]
Krauss et al., Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment, Protein Eng., 16(10):753-9 (2003).
[cited by applicant]
Kreitman et al., Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia, J. Clin. Oncol., 30(15):1822-8 (2012).
[cited by applicant]
U.S. Provisional Application filed on Jun. 25, 2015 by ICell Gene Therapeutics LLC, U.S. Appl. No. 62/184,321.
[cited by applicant]
Vallera et al., “A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphma,” Clin Cancer Res 11(10):3879-3888 (2005).
[cited by applicant]
Wen et al., The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia, J. Immunol., 188(3):1075-82 (2012).
[cited by applicant]
Wilkie et al., 1070Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling, J. Clin. Immunol., 32:1059-1070 (2012).
[cited by applicant]
Xiao et al., Identification and characterization of fully human anti-CD22 monoclonal antibodies, MAbs, 1(3):297-303 (2009).
[cited by applicant]
Yang et al., Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition, Gene. Ther., 15:1411-1423 (2008).
[cited by applicant]
Yazawa et al., Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease, Proc. Natl. Acad. Sci. USA, 102(42):15178-83 (2005).
[cited by applicant]
Yokose, et al., “CD20-positive T cell leukemia/lymphoma: case report and review of the literature,” Annals of Hematol., 80(6):372-375 (2001).
[cited by applicant]
Krontiris et al., Internal medicine, 4th Edition, Editor-in-chief Jay stein, Elsevier science, Chapters 71-72:699-729 (1994).
[cited by applicant]
Kumaresan et al., “Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection”, CrossMark, PNAS, 111:29, pp. 10660-10665 (Jul. 22, 2014).
[cited by applicant]
Kumaresan et al., “Dual-Specificity CAR+ T Cells to Target B-Cell Malignancies and Opportunistic Fungal Infection”, Biology of Blood and Marrow Transplantation, Abstracts from the 2014 BMT Tandem Meetings, Feb. 26-Mar. …
[cited by applicant]
Lanitis et al., Chimeric antigen receptor t cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo, Cancer Immunol. Res., 1:43-53 (2013).
[cited by applicant]
Leonard et al., Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma, J. Clin. Oncol., 21(16):3051-9 (2003).
[cited by applicant]
Likar et al., “The use of the mutated version of human Deoxycytiidinkiase as a reporter gene for the assessment of the adoption of the T-cell therapy,” Hematology, Oncology and Immunopathology in Pediatrics 11 (2):23-31…
[cited by applicant]
Likar et al., Use of Human Deoxycytidine Kinase Mutant Variant as a Reporter Gene for Evaluation of Adoptive T-Cell Therapy, Hematology, Oncology and Immunopathology in Pediatrics, 11(2):24-31 (2012).
[cited by applicant]
Liu et al., “Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector”, Scientific Reports. 7:2193, pp. 1-9 (May 19, 2017).
[cited by applicant]
Lohmueller, Jason Jakob, “Synthetic Biology Approaches to Engineering Human Cells”, Doctoral dissertation, Harvard University (Jan. 2013).
[cited by applicant]
Long et al., “Lessons learned from a highly-active CD22-specific chimeric antigen receptor,” OncoImmunoloqy 2:4, 323621, 4 paqes (2013).
[cited by applicant]
Long et al., 4-1 BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receiptors, Nature Med., 21 (6):581-90 (2015).
[cited by applicant]
Mackall et al., “Immune-based therapies for childhood cancer,” Nature Reviews, Clinical Oncology 11 :693-703 (2014).
[cited by applicant]
Maeda, et al., “Engineering of Functional Chimeric Protein G-Vargula Luciferase,” Analytical Biochemistry 249, Article No. AB972181, pp. 147-152 (1997).
[cited by applicant]
Maher, “Immunotherapy of Malignant Diseases Using Chimeric Antigen Receptor Engrafted T Cells,” ISRN Oncoloav, 23 paaes (2012).
[cited by applicant]
Mason et al., Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells, Blood, 69(3):836-40 (1987).
[cited by applicant]
Maude et al., “Chimeric antigen receptor T-cell therapy for ALL,” Hematology 559-564 (2014).
[cited by applicant]
Maus, et al., “T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans,” Cancer Immunol Res: 1(1), pp. 26-31 (Jul. 2013).
[cited by applicant]
Meeker et al., A unique human B lymphocyte antigen defined by a monoclonal antibody, Hybridoma, 3(4):305-20 (1984).
[cited by applicant]
Nicholson et al., Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma, Mol. Immunol., 34(16-17):1157-65 (1997).
[cited by applicant]
Opponent Comments filed in European Patent Office by Opponent James Poole Ltd. With respect to European Patent No. 3237442, based on European Patent Application No. 15817520.8, communication from EPO dated Apr. 1, 2021.
[cited by applicant]
Opposition Brief filed on behalf of Opponent James Poole Limited against European Patent No. 3237442 (forwarded by the EPO to D. Young on Apr. 17, 2020) (European Patent No. 3237442 is a foreign counterpart to the prese…
[cited by applicant]
Opposition Brief filed on behalf of Opponent Miltenyi Biotec B.V. & Co. KG against European Patent No. 3237442.
[cited by applicant]
Orentas et al., “Immunotherapy targets in pediatric cancer,” Frontiers in Oncology 2(3):1-16 (2012).
[cited by applicant]
Pakula et al., “Genetic analysis of protein stability and function,” Annual Review Genet. 23:289-310 (1989).
[cited by applicant]
Pegram et al., “CD28z CARs and Armored CARs,” Cancer J. 20(2):127-133 (2014).
[cited by applicant]
Pezzutto et al., Amplification of human B cell activation by a monoclonal antibody to the B cell-specific antiaen CD22, Bp 130/140, J. Immunol., 138(1):98-103 (1987).
[cited by applicant]
Pezzutto et al., CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation, J. Immunol., 138(9):2793-9 (1987).
[cited by applicant]
Qin et al., “Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22”, Molecular Therapy Oncolytics. vol. 11, pp. 127-137 (Dec. 21, 2018).
[cited by applicant]
Qin et al., Novel CD19/CD22 Bicistronic Chimeric Antigen Receptors outperform single or bivalent cars in eradicating CD19+CD22+, CD19-, and CD22- Pre-B leukemia, Blood. 130:810 (2017).
[cited by applicant]
Qin et al., Preclinical development of bispecific chimeric antigen receptor targeting both CD19 and CD22, Blood. 126:4427 (2015).
[cited by applicant]
Raponi et al., Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases, Leuk. Lymphoma, 52(6):1098-107 (2011).
[cited by applicant]
Response of the proprietor to the examination divisional in European Application No. 15817520.8 dated Oct. 16, 2018.
[cited by applicant]
Richman, et al., “High-Affinity GD2-Specific CART Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model,” Cancer Immunol Res: 6(1), pp. 36-46 (Jan. 2018).
[cited by applicant]
Riet,, Erhohung der Antigen-Selektivitat von T-Zellen durch Koexpression chimarer Antigen-Rezeptoren unterschiedlicher Spezifitat, PhD thesis, Universitat zu Kain (2010), Enalish abstract.
[cited by applicant]
Rieux-Laucat, et al., “Inherited and Somatic CD3zeta Mutations in a Patient with T-Cell Deficiency,” The New England Journal of Medicine, 354(18): 1913-1921 (2006).
[cited by applicant]
Roguska et al., A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing, Protein Eng., 9(10):895-904 (1996).
[cited by applicant]
Rossi et al., “Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus,” PLoS ONE 9(5):1-8 (2014).
[cited by applicant]
Rout, et al., “Cell interaction in the humoral immune response,” Immunology, 5th edition, pp. 194-217 (2000) (Mosby, Lindon).
[cited by applicant]
Sadelain et al., “The Basic Principles of Chimeric Antigen Receptor Design,” Cancer Discovery 3:388-398 (2013).
[cited by applicant]
Safdari, et al., “Antibody humanization methods—a review and update,” Biotechnology and Genetic Engineering Reviews, 29(2):175-86 (2013).
[cited by applicant]
Schamel, et al., “The TCR is an allosterically regulated macromolecular machinery changing its conformation while working,” Immunological Reviews; 291:8-25 (2019).
[cited by applicant]
Schwarting et al., The monoclonal antibodies alpha S-HCL 1 (alpha Leu-14) and alpha S-HCL 3 (alpha Leu-M5) allow the diagnosis of hairy cell leukemia, Blood, 65(4):974-83 (1985).
[cited by applicant]
Shi et al., “Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects,” Molecular Cancer 13:219, 8 pages (2014).
[cited by applicant]
Shih et al., Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2, Int. J. Cancer, 56(4):538-45 (1994).
[cited by applicant]
Srivastava et al., Engineering CAR-T cells: Design concepts, Trends Immunol., 36(8):494-502 (2015).
[cited by applicant]
Stratagene Catalog, Gene characterization kits, Stratagene Corp., 39 (1988).
[cited by applicant]
Summons to Attend Oral Proceedings issued on Jun. 4, 2021 in corresponding European Application No. 15817520.8 (European Patent No. 3237442)(11 pages), containing preliminary opinion from Opposition Division.
[cited by applicant]
Teplyakov, et al., “Antibody modeling assessment II. Structures of models,” Proteins, 82: 1563-1582 (2014).
[cited by applicant]
Tobias Riet: Inaugural doctoral Dissertation, 204 pages, Nov. 24, 2010.
[cited by applicant]
Turtle et al., CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J. Clin. Invest., 126(6):2123-2138 (2016).
[cited by applicant]
Kochenderfer J.N., et al., “Eradication of B-Lineage Cells and Regression of Lymphoma in a Patient Treated with Autologous T Cells Genetically Engineered to Recognize CD19,” Blood, 116(20): 4099-4102 (Nov. 2010)., Nov. …
[cited by applicant]
U.S. Appl. No. 17/923,626, filed Nov. 7, 2022, Srivastava et al.
[cited by applicant]
U.S. Appl. No. 18/153,990, filed Jan. 12, 2023, Pulé et al.
[cited by applicant]
U.S. Appl. No. 18/158,310, filed Jan. 23, 2023, Pulé et al.
[cited by applicant]
Apparent email communication involving publication date of [Full Lohmueller Citation] submitted to EPO in opposition proceeding against European Patent No. 3237442, dated Aug. 6, 2021, 2 pages.
[cited by applicant]
Blasi, R. D., et al., A Call for Caution in Analysing Mammalian Co-Transfection Experiments and Implications of Resource Competition in Data Misinterpretation, Nature Communications, 12(2545):1-6 (2021).
[cited by applicant]
Communication of a Notice of Opposition Brief filed on behalf of Opponent Miltenyi Biotec B.V. & Co. KG against European Patent No. 3237442, dated Apr. 15, 2020, 46 pages.
[cited by applicant]
Duong et al., Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer, Immunotherapy, 3(1):33-48 (2011).
[cited by applicant]
European Patent Application No. 19172397.2, Office action, dated Feb. 10, 2021, 4 pages.
[cited by applicant]
European Patent Application No. 19172397.2, Office Action, dated Jan. 18, 2022, 4 pages.
[cited by applicant]
European Patent Application No. 19172397.2, Response to Office Action, dated Sep. 15, 2021, 8 pages.
[cited by applicant]
Final Written Submission by Opponent (O2) James Poole Limited against European Patent No. 15817520.8, dated Jan. 28, 2022, 13 pages.
[cited by applicant]
Lee et al., T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancets, 385(9967):517-28 (2015).
[cited by applicant]
Luke G.A., et al., 2A to the Fore—Research, Technology and Applications, Biotechnology and Genetic Engineering Reviews, 26:235-272 (2009).
[cited by applicant]
Maude S.L., et al., CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia, Blood, 125(26):4017-4023 (2015).
[cited by applicant]
Pfutzner W., “Retroviral Bicistronic Vectors”, Drug News Perspect, 21(9):473-480 (2008).
[cited by applicant]
Roitt I., et al., Immunology, Fifth Edition, Mosby London, republished by MIR (Moscow), Chapter 1, pp. 4-6, (2000).
[cited by applicant]
Written Submission in Preparation for the Oral Proceedings by Opponent (O1) Miltenyi Biotec B.V. & Co. KG against European Patent No. 15817520.8, dated Jan. 29, 2022, 30 pages.
[cited by applicant]
Written Submission in Preparation for the Oral Proceedings by Opponent (O2) James Poole Limited against European Patent No. 15817520.8, dated Mar. 11, 2022, 9 pages.
[cited by applicant]
Haso et al., A new high activity anti-CD22 chimeric antigen receptor (CAR) targeting B cell leukemia, Blood, 120(21):2611 (2012).
[cited by applicant]
European Patent Application No. 23217769.1, Extended European Search Report, dated Apr. 30, 2024.
[cited by applicant]
Alvarez-Vallina et al., Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment CD28 receptors, Eur. J. Immunol., 26:2304-9 (1996).
[cited by applicant]
Goronzy et al., T-cell co-stimulatory pathways in autoimmunity, Arthritis Res Ther., 10 Suppl 1(Supp 1):S3 (2008).
[cited by applicant]
“Immune Mechanism Laboratory, Chosun University Department of Biology”, Molecular Cell Biology News, May 2012, 10 Pages.
[cited by applicant]
Meng et al., Engineering Cystoplasmic Signaling of CD28 CARs for Improved Therapeutic Functions, Frontiers in Immunology, vol. 11, Article 1046 (Jun. 19, 2020).
[cited by applicant]
Kindt et al., “Kuby Immunology”, Immunology Textbook, 3 Pages (Aug. 20, 2008).
[cited by applicant]
Wikipedia: “Co-stimulation”, Retrieved on Dec. 11, 2024, 11 Pages.
[cited by applicant]
Larson et al., CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours, Nature, 31 pages (Apr. 2022).
[cited by applicant]
Boulch et al., Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-gamma is a major determinant of CD4+ CAR T-cell antitumor activity, Nature Cancer, 4:968-83 (Jul. 2023).
[cited by applicant]
Zibelman et al., A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors, Nature Communications, 14:4513 (2023).
[cited by applicant]
Boyman et al., The role of interleukin-2 during homeostasis and activation of the immune system, Nat. Rev. Immunol., 12(3):180-90 (2012).
[cited by applicant]
Dummer et al., Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas, Mol. Ther., 1…
[cited by applicant]
Huppa et al., Continuous T cell receptor signaling required for synapse maintenance and full effector potential, Nat. Immunol., 4(8):749-55 (2003).
[cited by applicant]
Jing et al., Interferon-{circumflex over (l)}
[cited by applicant]
Rosenberg et al., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, Journal of the National Cancer Institute, 86(15):1159-66 (1994).
[cited by applicant]
Rosenberg et al., Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy, Clin. Cancer Res., 17(13):4550-7 (2011).
[cited by applicant]
Sarnaik et al., Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma, J. Clin. Oncol., 39(24):2656-66 (2021).
[cited by applicant]